Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). In addition, a 12 mg dose will be included in an open-label extension study for those children who